Side-by-side · Research reference
CagrilintidevsVesugen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BAnimal-MechanisticHUMAN-REVIEWED5/43 cited
Vesugen
Bioregulatory Tripeptide · Vascular Endothelium
3 AATripeptide
Endothelin-1 ↓Atherosclerotic tissue
Ki-67 ↑Aged endothelium
SQ / IM · Protocol varies
01Mechanism of Action
Parameter
Cagrilintide
Vesugen
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
Vascular endothelial cell nucleus — MKI67 gene promoter
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016Khavinson 2014
Feedback intact?
Yes — acts via physiological amylin pathways
Not applicable — does not operate via hormone axis
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
Vesugen
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Frequency
Once weekly (subcutaneous)Bailey 2026
Long-acting formulation.
Not specified in available literature
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Animal models (atherosclerosis, restenosis, aging) · Russian case series
Duration
26–52 weeks in trialsYamauchi 2026
Case series report treatment courses in elderly arterial insufficiency
Standard dose (reported)
—
Not standardised — Russian clinical case series
Protocols vary; no FDA-approved regimen.
Half-life
—
Not reported
Tripeptides typically cleared rapidly.
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
Vesugen
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
04Side Effects & Safety
Parameter
Cagrilintide
Vesugen
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Reported adverse events
—
None documented in available abstracts
Injection site
—
Assumed minimal — typical for small peptides
Long-term safety
—
Unknown — no long-term RCT data
Epigenetic mechanism risk
—
Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
Vesugen
—Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
Vesugen
- ·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context
05Administration Protocol
Parameter
Cagrilintide
Vesugen
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
—
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
Vesugen
+ Thymalin
Multi-pathwayBoth from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.
- Vesugen
- Per protocol (SQ/IM)
- Thymalin
- Per protocol (SQ/IM)
- Frequency
- Sequential or concurrent per geroprotective protocol
- Primary benefit
- Multi-system age-related decline mitigation (vascular + immune)